• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".

作者信息

Linschoten Marijke, Nab Linda, van der Horst Iwan C C, Tieleman Robert, Asselbergs Folkert W

机构信息

Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht University, P.O. Box 85500, 3584 CX Utrecht, The Netherlands.

Department of Clinical Epidemiology, Leiden University Medical Center, Postzone C7-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

出版信息

Int J Infect Dis. 2021 Feb;103:560-561. doi: 10.1016/j.ijid.2020.12.006. Epub 2020 Dec 9.

DOI:10.1016/j.ijid.2020.12.006
PMID:33310109
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7725132/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b485/7725132/3e3c58fd7720/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b485/7725132/3e3c58fd7720/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b485/7725132/3e3c58fd7720/gr1_lrg.jpg

相似文献

1
Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".对“早期使用羟氯喹而非氯喹可降低COVID-19患者入住重症监护病房的几率”的回应。
Int J Infect Dis. 2021 Feb;103:560-561. doi: 10.1016/j.ijid.2020.12.006. Epub 2020 Dec 9.
2
Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".对关于“早期使用羟氯喹而非氯喹可降低COVID-19患者入住重症监护病房的几率”的信件的回复
Int J Infect Dis. 2021 Feb;103:478-479. doi: 10.1016/j.ijid.2020.12.008. Epub 2020 Dec 9.
3
Comparison of hospital treatment strategy or of treatment actually received in COVID-19?: Commenting on: Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis. 2020 September.2019冠状病毒病（COVID-19）医院治疗策略或实际接受治疗情况的比较：对以下文献的评论：Lammers AJJ、Brohet RM、Theunissen REP、Koster C、Rood R、Verhagen DWM等。早期使用羟氯喹而非氯喹可降低COVID-19患者入住重症监护病房的几率。《国际传染病杂志》。2020年9月。
Int J Infect Dis. 2021 Feb;103:516. doi: 10.1016/j.ijid.2020.12.007. Epub 2020 Dec 9.
4
Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.氯喹和羟氯喹治疗新型冠状病毒肺炎：希望与谨慎并存
Clin Toxicol (Phila). 2021 Jan;59(1):70-71. doi: 10.1080/15563650.2020.1748194. Epub 2020 Apr 2.
5
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.抗2019冠状病毒病（COVID-19）的氨基喹啉：氯喹或羟氯喹。
Int J Antimicrob Agents. 2020 Apr;55(4):105945. doi: 10.1016/j.ijantimicag.2020.105945. Epub 2020 Mar 17.
6
Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.在 SARS-CoV-2（COVID-19）紧急情况下预防耳毒性。
J Glob Antimicrob Resist. 2020 Dec;23:263-264. doi: 10.1016/j.jgar.2020.09.030. Epub 2020 Oct 17.
7
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.氯喹和羟氯喹在2019冠状病毒病中的应用：对医疗保健专业人员的实践启示
J Coll Physicians Surg Pak. 2020 Oct;30(10):124-128. doi: 10.29271/jcpsp.2020.supp2.124.
8
Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?氯喹或羟氯喹对治疗新型冠状病毒肺炎患者或预防接触过该病毒的人感染是否有效？
Saudi Med J. 2021 Mar;42(3):342-343.
9
Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?使用氯喹或羟氯喹治疗新型冠状病毒肺炎：这是否符合伦理？
Cent Eur J Public Health. 2020 Sep;28(3):246-247. doi: 10.21101/cejph.a6464.
10
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.氯喹和羟氯喹治疗 COVID-19 的紧急授权。
Ann Pharmacother. 2020 Aug;54(8):827-831. doi: 10.1177/1060028020925558. Epub 2020 May 9.

引用本文的文献

1
Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study.年龄是 COVID-19 相关住院死亡率的主要决定因素，而既往合并症的影响最小，这是一项回顾性队列研究。
BMC Geriatr. 2022 Mar 5;22(1):184. doi: 10.1186/s12877-021-02673-1.
2
Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized With COVID-19: A Multicenter Cohort Study.COVID-19 住院患者的缺血性脑卒中风险、临床病程和结局：一项多中心队列研究。
Stroke. 2021 Dec;52(12):3978-3986. doi: 10.1161/STROKEAHA.121.034787. Epub 2021 Nov 4.

本文引用的文献

1
Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.早期使用羟氯喹而不是氯喹可降低 COVID-19 患者的 ICU 入院率。
Int J Infect Dis. 2020 Dec;101:283-289. doi: 10.1016/j.ijid.2020.09.1460. Epub 2020 Sep 29.
2
CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic.CAPACITY-COVID：一项欧洲登记研究，旨在确定心血管疾病在新冠疫情中的作用。
Eur Heart J. 2020 May 14;41(19):1795-1796. doi: 10.1093/eurheartj/ehaa280.
3
Competing risks in epidemiology: possibilities and pitfalls.
流行病学中的竞争风险：可能性与陷阱。
Int J Epidemiol. 2012 Jun;41(3):861-70. doi: 10.1093/ije/dyr213. Epub 2012 Jan 9.
4
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.队列研究中的不朽时间偏倚问题：以他汀类药物预防糖尿病进展为例
BMJ. 2010 Mar 12;340:b5087. doi: 10.1136/bmj.b5087.